On The Radar – 24th Edition
By
Traditional PBM contracts often contain multiple hidden revenue streams, including spread pricing, rebates, administrative fees, specialty pharmacy markups, and pharmacy clawbacks. Industry experts argue that meaningful cost containment requires structural reform, not just isolated transparency measures.
➡ Why it matters: Employers are realizing that pharmacy costs cannot be controlled without understanding how every dollar flows through the supply chain.
A new report argues that administrative complexity is one of the largest drivers of U.S. healthcare spending. From PBM rebate structures to insurer upcoding and consolidation-driven markups, layers of intermediaries continue to add cost without improving care.
➡ Why it matters: Rising healthcare costs are increasingly tied to system complexity rather than clinical care itself.
Researchers are drawing renewed attention to “patent thickets,” where manufacturers build extensive layers of overlapping patents that delay generic competition. These strategies can extend market exclusivity for years beyond the original patent lifecycle.
➡ Why it matters: Delayed generic competition keeps costs elevated for employers, health plans, and patients long after a drug’s original innovation period.
Industry experts say PBM pharmacy audits are facing unprecedented scrutiny as questions grow around whether audit recoveries are improving plan performance or simply generating additional revenue streams. New transparency requirements could shine more light on how these funds are used.
➡Why it matters: Increased oversight may help employers better understand whether audit-related savings are actually benefiting their health plans.
A growing number of analysts argue that rebate-driven drug pricing continues to distort competition. When rebates are tied to higher list prices, lower-cost alternatives can struggle to gain traction despite offering similar clinical value.
➡Why it matters: Misaligned incentives remain one of the biggest barriers to lower prescription drug costs.
GLP-1 medications now account for more than 10% of employer prescription claims, according to new survey data. The rapid growth is forcing employers to rethink pharmacy benefit strategies while balancing employee demand and financial sustainability.
➡Why it matters: GLP-1s have shifted from a trend to a major budget category that employers can no longer ignore.
More than half of patients report challenges obtaining medications, with high costs and prior authorization delays leading many to abandon prescriptions altogether. Digital tools that provide real-time benefit information are gaining traction as a potential solution.
➡ Why it matters: Access barriers don’t just affect patient outcomes. They can also increase long-term healthcare costs when treatment is delayed.
Mark Cuban continues advocating for direct-pay healthcare models that bypass traditional insurance structures. His approach emphasizes transparent pricing, direct provider contracts, and simplified payment systems designed to reduce administrative overhead.
➡ Why it matters: Alternative purchasing models are gaining attention as employers search for new ways to control healthcare spending.
Employers are increasingly moving toward unbundled and pass-through PBM arrangements that eliminate hidden revenue streams and replace them with predictable administrative fees. Fiduciary pressure and regulatory scrutiny are accelerating the transition.
➡ Why it matters: Transparency is becoming a competitive advantage, not just a compliance requirement.
As patent expirations loom, pharmaceutical M&A activity is rebounding. Drugmakers are pursuing acquisitions to replenish pipelines, while biotech firms are preparing for increased investor and buyer interest.
➡ Why it matters: The next wave of pharmaceutical innovation may be driven as much by acquisitions as by internal research and development.
Final Thoughts
Healthcare affordability remains under pressure from multiple directions: rising specialty drug costs, growing GLP-1 utilization, patent-driven pricing strategies, and increasingly complex supply chains. At the same time, transparency is no longer optional. Employers, regulators, and patients are demanding clearer answers about where healthcare dollars go and who ultimately benefits.
We’ll be back in two weeks with more news you need to know. If you’d like a custom analysis or want to explore SHARx program options for your clients, contact us!
Stay Connected with SHARx
Subscribe to our newsletter for monthly updates from our CEO, curated industry news, insights from our in-house pharmacist, the latest blog posts, and more. Just fill out the form to stay informed.
Newsletter Sign-up
Be the first to learn what’s new with SHARx.